Table 2 Patient demographics: other therapy.
From: Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
No. (%) | |
|---|---|
Radiation for primary disease | 6 (33.3) |
Radiation for metastatic disease | 9 (50.0) |
Radiation for CNS disease | 11 (61.1) |
Before trial participation | 8 (44.4) |
After trial participation | 3 (16.7) |
Surgery for primary disease | 13 (72.2) |
Surgery for metastatic disease | 9 (50.0) |
Surgery for CNS disease | 5 (27.8) |
Before trial participation | 5 (27.8) |
After trial participation | 1 (5.6) |
Systemic therapy for primary disease | 11 (61) |
Systemic therapy for metastatic disease | 9 (50.0) |
Patients receiving corticosteroids, no. (%) | 14 (77.8) |
